KALA
Kala Pharmaceuticals Inc
NASDAQ: KALA · HEALTHCARE · BIOTECHNOLOGY
$0.11
-3.93% today
Updated 2026-04-30
Market cap
$110.98M
P/E ratio
—
P/S ratio
23.75x
EPS (TTM)
$-3.31
Dividend yield
—
52W range
$0 – $21
Volume
9.1M
Kala Pharmaceuticals Inc (KALA) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
0.00%
ROE
-279.20%
ROA
-81.60%
Debt/equity
-3.58x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2013 | $50000.00 | $-10.65M | — | -22,264.00% | -21,306.00% |
| 2014 | $455000.00 | $-19.36M | -2,945.93% | -3,920.88% | -4,255.16% |
| 2015 | $45000.00 | $-16.68M | 100.00% | -35,435.56% | -37,071.11% |
| 2016 | $0.00 | $-33.17M | — | — | — |
| 2017 | $0.00 | $-42.21M | — | — | — |
| 2018 | $0.00 | $-66.74M | — | — | — |
| 2019 | $6.07M | $-94.35M | 53.11% | -1,452.49% | -1,553.29% |
| 2020 | $6.36M | $-104.33M | 50.13% | -1,512.59% | -1,639.85% |
| 2021 | $11.24M | $-142.60M | 63.55% | -973.60% | -1,268.73% |
| 2022 | $3.89M | $-44.82M | 34.22% | -2,090.34% | -1,151.64% |
| 2023 | $0.00 | $-42.20M | — | — | — |
| 2024 | $0.00 | $-38.51M | — | — | — |
| 2025 | $0.00 | $-26.98M | — | — | — |